Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPRF | P10586 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909136 | 0.82 | SETD7 (0.46) | SETD7PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL23909134 | 0.82 | SETD7 (0.46) | SETD7PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL23909137 | 0.82 | SETD7 (0.46) | SETD7PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL28599777 | 0.79 | — | — | |
| SCHEMBL28518152 | 0.79 | — | — | |
| Boric Acid SCHEMBL28949539 | 0.78 | — | — | |
| Acrylic Acid SCHEMBL28430309 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL28982681 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL28982682 | 0.78 | — | — | |
| SCHEMBL28395803 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-110694690-A | Method for preparing metal monatomic catalyst | 苏州大学 | 2020-01-17 | — | — | CN | disclosed |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC | 2019-06-20 | — | — | US | disclosed |
| EP-3471774-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | Oncoselect Therapeutics, LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017218959-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | ONCOSELECT THERAPEUTICS, LLC (US) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | SETD7 1199/4885PTPRC 716/4885PTPRF 585/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | SETD7 1199/4885PTPRC 716/4885PTPRF 585/4885 |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | TK2, KIT, HCCS | SETD7 486/4885PTPRC 283/4885PTPRF 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.